

# Jean Charles Nault

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4729887/publications.pdf>

Version: 2024-02-01

99  
papers

10,395  
citations

61977

43  
h-index

36025

97  
g-index

103  
all docs

103  
docs citations

103  
times ranked

12314  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 616-626.	12.1	106
2	Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 905-917.	3.9	8
3	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. <i>Liver International</i> , 2022, 42, 492-506.	3.9	20
4	Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters. <i>United European Gastroenterology Journal</i> , 2022, 10, 8-9.	3.8	3
5	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2022, 109, 455-463.	0.3	7
6	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	10.7	36
7	Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 1470-1481.	0.9	0
8	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2022, 14, 2634.	3.7	0
9	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
10	Benign liver tumours: understanding molecular physiology to adapt clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 703-716.	17.8	11
11	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	7.3	104
12	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	3.7	54
13	Genomics of Viral Hepatitis-Associated Liver Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1827.	2.4	7
14	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101731.	1.5	2
15	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF BENIGN LIVER TUMOURS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101765.	1.5	3
16	Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 142-150.	2.8	5
17	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	7.3	129
18	<i>RSPO2</i> abnormal transcripts result from read-through in liver tumours with high $\beta$ -catenin activation and <i>CTNNB1</i> mutations. <i>Gut</i> , 2020, 69, 1152-1153.	12.1	3

#	ARTICLE	IF	CITATIONS
19	Acute pericarditis: A rare complication of gastric variceal obturation with cyanoacrylate glue. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, e25-e28.	1.5	3
20	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020, 69, 737-747.	12.1	78
21	TIPS for management of portal-hypertension-related complications in patients with cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 249-263.	1.5	22
22	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	12.1	17
23	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	3.7	44
24	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
25	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 990-1002.	3.7	101
26	Optimizing curative management of hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 109-115.	3.9	19
27	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	3.7	311
28	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	3.7	39
29	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP36.	4.2	12
30	Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. <i>Liver Cancer</i> , 2019, 8, 172-185.	7.7	22
31	Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 86-94.	0.9	14
32	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. <i>Immunotherapy</i> , 2019, 11, 1005-1013.	2.0	21
33	Natural history of liver adenomatosis: A long-term observational study. <i>Journal of Hepatology</i> , 2019, 71, 1184-1192.	3.7	32
34	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	1.3	141
35	The role of telomeres and telomerase in cirrhosis and liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 544-558.	17.8	154
36	A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1477-1479.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019, 8, 1615818.	4.6	34
38	A 17 $\alpha$ - $\beta$ -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , 2019, 70, 231-240.	7.3	75
39	Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?. <i>Gastroenterology</i> , 2019, 156, 1558-1560.	1.3	4
40	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. <i>Gastroenterology</i> , 2019, 156, 492-509.	1.3	145
41	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. <i>International Journal of Cancer</i> , 2019, 144, 533-544.	5.1	72
42	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 336-344.	3.7	47
43	The role of molecular enrichment on future therapies in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 237-247.	3.7	95
44	Macrotrabecular $\alpha$ -massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	7.3	159
45	Reply to: "Response to: Positron emission tomography/computed tomography with 18 F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma" <i>Journal of Hepatology</i> , 2018, 69, 555-556.	3.7	2
46	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	7.3	43
47	Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. <i>Journal of Hepatology</i> , 2018, 68, 783-797.	3.7	271
48	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	12.8	118
49	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. <i>New England Journal of Medicine</i> , 2018, 379, 1178-1180.	27.0	15
50	Molecular classification of hepatocellular adenomas: impact on clinical practice. <i>Hepatic Oncology</i> , 2018, 5, HEP04.	4.2	34
51	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2017, 23, 4364-4375.	7.0	57
52	Cancer Gene Discovery in Hepatocellular Carcinoma: The $\alpha$ CRISPR/CAS9 Accelerator. <i>Gastroenterology</i> , 2017, 152, 941-943.	1.3	3
53	Autoimmune $\alpha$ -like chronic hepatitis induced by olmesartan. <i>Hepatology</i> , 2017, 66, 2086-2088.	7.3	8
54	Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. <i>Radiology</i> , 2017, 284, 877-886.	7.3	120

#	ARTICLE	IF	CITATIONS
55	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	3.7	525
56	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	3.7	31
57	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	1.3	290
58	Molecular classification of hepatocellular adenoma in clinical practice. <i>Journal of Hepatology</i> , 2017, 67, 1074-1083.	3.7	119
59	Molecular targets for HCC and future treatments. <i>Journal of Hepatology</i> , 2017, 66, 234-235.	3.7	7
60	Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. <i>Oncotarget</i> , 2017, 8, 32190-32200.	1.8	15
61	Genotype-phenotype correlation of CTNNB1 mutations reveals different $\beta$ -catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	7.3	222
62	Type 2 diabetes-associated hepatocellular carcinoma: A molecular profile. <i>Clinical Liver Disease</i> , 2016, 8, 53-58.	2.1	11
63	Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results. <i>Radiology</i> , 2016, 280, 611-621.	7.3	100
64	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1095271.	0.7	12
65	Stemness of liver cancer: From hepatitis B virus to Wnt activation. <i>Journal of Hepatology</i> , 2016, 65, 873-875.	3.7	6
66	Hepatocellular Carcinoma: the Impact of NAFLD. <i>Current Hepatology Reports</i> , 2016, 15, 190-198.	0.9	2
67	Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. <i>Journal of Hepatology</i> , 2016, 65, 663-665.	3.7	103
68	The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population. <i>Medicine (United States)</i> , 2016, 95, e5263.	1.0	6
69	The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. <i>Digestive and Liver Disease</i> , 2016, 48, 1088-1092.	0.9	14
70	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016, 65, 1031-1042.	3.7	219
71	Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1906-1915.	1.5	8
72	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. <i>Modern Pathology</i> , 2016, 29, 43-50.	5.5	45

#	ARTICLE	IF	CITATIONS
73	TERT promoter mutations in primary liver tumors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 9-14.	1.5	78
74	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	1.3	980
75	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	21.4	1,372
76	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1786-1788.	7.0	73
77	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	21.4	387
78	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, 869-876.	0.9	46
79	Reports from the International Liver Cancer Association (ILCA) congress 2014. <i>Journal of Hepatology</i> , 2015, 62, 477-482.	3.7	7
80	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. <i>Gut</i> , 2015, 64, 820-829.	12.1	127
81	Molecular Determinants of Prognosis in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 31-6.	1.4	3
82	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	3.6	47
83	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	16.8	240
84	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. <i>Hepatology</i> , 2014, 60, 1983-1992.	7.3	268
85	Pathogenesis of hepatocellular carcinoma according to aetiology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 937-947.	2.4	59
86	Genetics of hepatocellular carcinoma: The next generation. <i>Journal of Hepatology</i> , 2014, 60, 224-226.	3.7	59
87	Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 730-1.	2.2	3
88	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , 2013, 4, 2218.	12.8	513
89	Predisposition to hepatocellular carcinoma: Clues in sex chromosomes. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 547-548.	1.5	0
90	Hepatocellular Benign Tumors – From Molecular Classification to Personalized Clinical Care. <i>Gastroenterology</i> , 2013, 144, 888-902.	1.3	251

#	ARTICLE	IF	CITATIONS
91	Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. <i>Gastroenterology</i> , 2013, 145, 53-55.	1.3	10
92	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	1.3	302
93	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncolmmunology</i> , 2013, 2, e27090.	4.6	39
94	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1343-1352.	2.5	65
95	Molecular Classification of Hepatocellular Adenomas. <i>International Journal of Hepatology</i> , 2013, 2013, 1-7.	1.1	24
96	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	3.7	354
97	Genetics of Hepatobiliary Carcinogenesis. <i>Seminars in Liver Disease</i> , 2011, 31, 173-187.	3.6	138
98	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	8.5	218
99	Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. <i>Liver Cancer International</i> , 0, , .	1.3	0